Add- Aspirin

 Oncology / Posted 2 years ago

 A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumours.


  • Inclusion Criteria : 1. Written informed consent 2. WHO performance status 0, 1 or 2 3. Previous or current participants of other primary treatment trials if agreed in advance between trials 4. No clinical or radiological evidence of residual or distant disease
  • Exclusion Criteria : Please speak to your clinician
  • Study start date : 05/10/2015
  • Study end date : 01/08/2021
  • Wales-Based Study Contact : Not recruiting in Wales
  • Principal Investigator : Dr Ruth Langley

No post found